FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
April 19, 2018

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Moon Hee V. Choi, PharmD
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

G. Caleb Alexander, MD, MS
(Chairperson)
Associate Professor of Epidemiology and Medicine
Johns Hopkins Bloomberg School of Public Health
Center for Drug Safety and Effectiveness
Baltimore, Maryland

Mark W. Green, MD, FAAN
Professor of Neurology, Anesthesiology, and Rehabilitation Medicine
Director of Headache and Pain Medicine
Vice Chair of Neurology for Professional Development and Alumni Relations
Icahn School of Medicine at Mt Sinai
New York, New York

David S. Knopman, MD
Professor of Neurology
Mayo Clinic
Rochester, Minnesota

Richard J. Kryscio, PhD
Professor, Statistics and Biostatistics
University of Kentucky
Sanders-Brown Center on Aging
Lexington, Kentucky

Chiadi U. Onyike, MD, MHS
Associate Professor of Psychiatry and Behavioral Sciences
Division of Geriatric Psychiatry and Neuropsychiatry
Department of Psychiatry and Behavioral Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel S. Perlmutter, MD
Elliot Stein Family Professor of Neurology
Professor of Radiology, Neuroscience, Physical Therapy & Occupational Therapy
Washington University School of Medicine
St. Louis, Missouri

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Mark Forrest Gordon, MD
Senior Director
Clinical Development, Neurology and Psychiatry
Teva Pharmaceuticals
Malvern, Pennsylvania
TEMPORARY MEMBERS (Voting)

Jane B. Acri, PhD  
Chief, Medication Discovery & Toxicology Branch  
Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse  
National Institutes of Health (NIH)  
Bethesda, Maryland

Danielle Bovce, MPH  
(Patient Representative)  
Senior Research Data Analyst  
Johns Hopkins University  
Baltimore, Maryland

José E. Cavazos, MD, PhD  
Professor of Neurology, Neuroscience, and Physiology  
Assistant Dean & Director, MD/PhD Program  
University of Texas Health San Antonio  
San Antonio, Texas

Harriet de Wit, PhD  
Professor  
Department of Psychiatry and Behavioral Neuroscience  
University of Chicago  
Chicago, Illinois

Richard P. Hoffman, PharmD  
(Acting Consumer Representative)  
Pharmacist/Medical Writer  
Hernando, Florida

John Mendelson, MD  
Senior Research Scientist, Friends Research Institute  
Founder and Chief Medical Officer, Ria Health  
San Francisco, California

Eluen Ann Yeh, MA, MD, FRCPC, Dip ABPN  
Associate Professor, Faculty of Medicine  
University of Toronto  
Director, Pediatric MS and Demyelinating Disorders Program  
Associate Scientist, Neurosciences and Mental Health, SickKids Research Institute  
Staff Physician, Division of Neurology  
The Hospital for Sick Children, Toronto, Ontario, Canada

FDA PARTICIPANTS (Non-Voting)

Ellis Unger, MD  
Director, Office of Drug Evaluation I (ODE-I)  
Office of New Drugs (OND), CDER, FDA

Robert Temple, MD  
Deputy Director  
ODE-I, OND, CDER, FDA

Billy Dunn, MD  
Director, Division of Neurology Products (DNP)  
ODE-I, OND, CDER, FDA

Eric Bastings, MD  
Deputy Director  
DNP, ODE-I, OND, CDER, FDA

Teresa Buracchio, MD  
Clinical Team Leader  
DNP, ODE-I, OND, CDER, FDA

Dominic Chiapperino, PhD  
Acting Director, Controlled Substance Staff  
Office of the Center Director, CDER, FDA